We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 240

Sandoz Inc. v. Amgen Inc.
  • Merchant & Gould
  • USA
  • June 16 2017

In a unanimous decision in Sandoz Inc. v. Amgen Inc., the U.S. Supreme Court held that injunctive relief was not available under federal law to


CAFC Finds ANDA Infringement Despite Differences Between FDA Labeling And Claim Language
  • Foley & Lardner LLP
  • USA
  • May 23 2017

In a non-precedential decision issued in Braintree Labs., Inc. v. Breckenridge Pharmaceutical, Inc., the Federal Circuit reversed the district


CFAD Fails to Knock Out 4 Acorda Patents to Multiple Sclerosis Drug
  • Marshall Gerstein & Borun LLP
  • USA
  • April 10 2017

A recent set of final written decisions in four IPRs against Acorda Therapeutics puts more marks in the loss column for Kyle Bass and the Coalition


Personalized Medicine: Insights Into Current Legal Issues
  • Foley & Lardner LLP
  • USA
  • September 18 2016

In his January 20, 2015 State of the Union Address, President Obama brought to the nation’s attention the promise of personalized medicine when he


Arm’s Length Royalty Rates Save Medtronic from $1.36 Billion Tax Deficiency
  • McDermott Will & Emery
  • USA
  • July 26 2016

Addressing whether certain intercompany technology license agreements were negotiated at arm's length, the US Tax Court rejected the Internal Revenue


“Providing . . . information” Step Given No Patentable Weight
  • Marshall Gerstein & Borun LLP
  • USA
  • July 22 2016

The PTAB recently addressed the limits on strategies to patent drug labeling, canceling claims directed to a method of supplying a pharmaceutical


Expanding access to experimental drugs
  • Duane Morris LLP
  • USA
  • June 4 2015

Drug and biologic developers have faced increasing pressure from patients and their advocates to make investigational drugs available for


U.S. House introduces Bill on federal oversight of compounding pharmacies
  • Duane Morris LLP
  • USA
  • September 19 2013

On September 12, 2013, U.S. Representative Morgan Griffith (R-Va.) introduced H.R. 3089 ("the House Bill"), which proposes a structure for federal


To carve out or not to carve out that is the question
  • Fish & Richardson PC
  • USA
  • April 15 2013

In April, this column talked about Orange Book use codes in the wake of Caraco v. Novo Nordisk,132 S.Ct. 1670 (2012) and how overbroad use codes may


How the new multi-party patent infringement rulings will affect pharmaceutical treatment claims
  • Hamilton Brook Smith & Reynolds PC
  • USA
  • July 26 2011

The very recent and continuing focus by the U.S. Supreme Court and the Federal Circuit sitting en banc on multi-party infringement issues namely, induced infringement and divided, or joint, infringement portends daunting new challenges for brand pharmaceutical companies that attempt to assert method of treatment claims in Hatch-Waxman litigation against generic competitors.